Medical Technology

Epigenomics AG is a Berlin, Germany based molecular diagnostics company developing and commercialising a pipeline of proprietary products for cancer. The firm’s lead product, Epi proColon, has been marketed in Europe since the end of 2009. In early 2013, the US FDA accepted Epigenomics’ Premarket Approval application for Epi proColon and also granted priority review status to the application. We initiated coverage in June 2013.
Recent reports